Pharmazeutische Aspekte von Topotecan-Infusionen

Pharmazeutische Zeitung

Volumn 142, Issue 31, 1997, Pages 30-33

  Krämer, Irene ^a   Thiesen, Judith ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; TOPOTECAN;

AREA UNDER THE CURVE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG STRUCTURE; FEMALE; HUMAN; OVARY CARCINOMA; PHARMACOKINETICS; SHORT SURVEY;

EID: 0030787038     PISSN: 00317136     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Fassberg, J., u. V. J. Stella, A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. Pharm. Sei. 81 (1992) 676-684.
2. Herben, V. M. M., et al. Clinical pharmacokinetics of Topotecan. Clin. Pharmacokinet. 31 (1996) 85-102.
3. Hycamtin® Produktmonographie. SmithKline Beecham, März 1997.
4. Hycamtin® Standardinformation für Krankenhausapotheker. SmithKline Beecham, Februar 1997.
5. Kearney, A. S., et al., Preformulation studies to aid the development of a ready-to-use injectable solution of the antitumor agent, topotecan. Int. J. Pharm. 127 (1996) 229 - 237.
6. Krämer, I., u. J. Thiesen, Chemical stability of topotecan hydrochloride in PVC bags and elastomeric portable infusion devices. In Vorbereitung. Metz, G., Neu gegen Krebs. Topoisomerase-Inhibitoren. Pharmazeutische Ztg. 140 (1995) 4232 4237.
7. Underberg, W. J. M., et al., Equilibrium kinetics of the new experimental antitumour compound SK&F 104864-A in aqueous solution. J. Pharm. Biomed. Anal. 8 (1990) 681 - 683. Van Warmerdam, L. J. C., et al, Pharmakokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure. Cancer Chemother. Pharmacol. 38 (1996) 254 - 260.